Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brelovitug + cavrotolimod
- Development stage
- Unknown
- Lead developer
- BlueJay Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Brelovitug + cavrotolimod is a combination therapeutic regimen under investigation by Bluejay Therapeutics for the treatment of chronic hepatitis B (CHB). Brelovitug (formerly BJT-778) is a potent human monoclonal antibody directed against the hepatitis B surface antigen (HBsAg), designed to reduce viral load and clear circulating HBsAg to help restore the patient's immune response. Cavrotolimod (formerly AST-008) is a Toll-like receptor 9 (TLR9) agonist utilizing spherical nucleic acid (SNA) technology to induce a robust innate immune response, including the production of Type I interferons. By combining antigen clearance with immune activation, the regimen aims to achieve a functional cure for CHB. The combination is currently being evaluated in Phase 2 clinical trials.
- Other names
- BJT-778 + AST-008
02
Targets
HBsAg (Hepatitis B surface antigen)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on brelovitug + cavrotolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brelovitug + cavrotolimod.